Positive Phase 2 Results for the VEGF Trap-Eye
- Details
- Category: Bayer
Bayer HealthCare and development partner Regeneron Pharmaceuticals, Inc. today announced positive results from a Phase 2 study evaluating the VEGF Trap-Eye in the neovascular form of age-related macular degeneration (wet AMD), one of the leading causes of blindness in adults. The VEGF Trap-Eye met both the primary study endpoint of a statistically significant reduction in retinal thickness and the key secondary endpoint of improvement of visual acuity after 12 weeks.
Novartis and Massachusetts Institute of Technology (MIT) in new partnership
- Details
- Category: Novartis
Novartis and the Massachusetts Institute of Technology have launched a long-term research collaboration aimed at transforming the way pharmaceuticals are produced. The 10-year partnership, known as the Novartis-MIT Center for Continuous Manufacturing, will work to develop new technologies that could replace the conventional batch-based system in the pharmaceuticals industry - which often includes many interruptions and work at separate sites - with continuous manufacturing processes from start to finish.
Bristol-Myers Squibb Finalizes Settlement of Previously Disclosed Federal Investigation
- Details
- Category: Bristol-Myers Squibb
Bristol-Myers Squibb Company (NYSE: BMY) announced that it has finalized a civil settlement agreement with the United States Department of Justice ("DOJ") and the Office of the United States Attorney for the District of Massachusetts resolving the previously disclosed investigations that began several years ago involving the company's drug pricing, and sales and marketing activities.
Takeda to Sponsor Berlin Marathon 2007
- Details
- Category: Takeda
Takeda Pharmaceutical Company Limited announced its official sponsorship of Berlin Marathon 2007 to be held on Sunday September 30, which will expand Takeda's support for marathon to Europe, as Takeda has been sponsoring Hokkaido Marathon in Japan for 13 years while started its sponsorship for The LaSalle Bank Chicago Marathon last year.
Prix Galien USA Names HUMIRA Best Biotechnology Product
- Details
- Category: Abbott
Abbott (NYSE: ABT), a leader in the treatment of autoimmune diseases, has received the 2007 Galen Prize for Best Biotechnology Product for HUMIRA (R) (adalimumab), the first approved fully human antibody. HUMIRA is approved for use in the treatment of moderate to severe rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and moderate to severe Crohn's disease.
Start of Phase 3 Program with Alemtuzumab for Treatment of Multiple Sclerosis
- Details
- Category: Bayer
Bayer Schering Pharma AG, Germany, and Genzyme Corporation, USA, today announced that the first patient has been treated in the first of two planned Phase 3 trials examining the safety and efficacy of alemtuzumab for the treatment of multiple sclerosis (MS).
Anti-Tumor Activity of Single-Agent Sunitinib Malate in Advanced Gastric Cancer
- Details
- Category: Pfizer
Preliminary results from a new Phase II study provide data on the anti-tumor activity and tolerability of sunitinib malate in patients with advanced gastric cancer. Additionally, data from phase I studies provide information on the tolerability and safety of sunitinib malate in combination with current standard of care chemotherapies in the treatment of hormone-refractory prostate cancer (HRPC) and advanced breast cancer.
More Pharma News ...
- Start of the TALENT Study - a Unique Antihypertensive Study in Europe
- Nycomed and NPS Pharmaceuticals Announce Licensing Agreement for GATTEX™
- FDA Accepts sNDA for Expanded Use of Angiomax®
- Protherics licenses its Covaccine HT adjuvant to Nobilon for influenza vaccine indications
- Bristol-Myers Squibb to Acquire Adnexus Therapeutics
- Protherics signs ReGel⢠licensing agreement with Myungmoon Pharm
- Lundbeck in-licenses Circadin®, a drug approved for the treatment of primary insomnia